Organon Follistim Sales Aid Cited For Misleading Cost-Effectiveness Claims
Executive Summary
An Organon sales brochure for the infertility agent Follistim makes misleading cost-effectiveness claims, FDA's Division of Drug Manufacturing, Advertising & Communications said in a Dec. 12 letter